EGFR inhibition in NSCLC: the emerging role of cetuximab.
Herbst RS. EGFR inhibition in NSCLC: the emerging role of cetuximab. Journal Of The National Comprehensive Cancer Network 2004, 2 Suppl 2: s41-51. PMID: 19780245.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsCell lung cancerTyrosine kinase inhibitorsLung cancerReceptor inhibitorsKinase inhibitorsAdvanced non-small cell lung cancerMonoclonal antibodiesEpidermal growth factor receptor expressionChemotherapy-related toxicityGrowth factor receptor expressionGrowth factor receptor inhibitionRole of cetuximabPhase II trialInterstitial lung diseaseEpidermal growth factor receptor inhibitionOverall response rateFactor receptor expressionModerate rashII trialUntreated patientsHypersensitivity reactionsLung disease